HURA
TuHURA BiosciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HURA
Tuhura Biosciences, Inc.
A biopharmaceutical company focused on the development and commercialization of new solid tumor cancer therapies
10500 University Center Dr., Suite 110, Tampa, FL 33612
--
TuHURA Biosciences, Inc., a Nevada corporation, was founded on June 24, 2009 as Berry Only, Inc. The company is a clinical-stage biopharmaceutical company. Kintara is committed to developing novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapies to reduce risk and address clear unmet medical needs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).
Company Financials
EPS
HURA has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.15, beating expectations. The chart below visualizes how HURA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
